HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells to extend healthy lifespan.
heXem bio has raised $10.4M in total funding. The most recent round was Seed. The last funding was announced in September 2026.
heXem bio's investors include Alumni Ventures, Gaingels, Draper Associates, Seraphim Space, Boost VC.
heXem bio is headquartered in Los Angeles, United States.
HexemBio develops a synthetic human Yolk Sac platform to rejuvenate blood stem cells to extend healthy lifespan.
heXem bio is at the Seed stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"heXem bio — Funding & Investors." VCBacked, September 15, 2026, https://www.vcbacked.co/company/hexem-bio. Accessed November 15, 2026.
VCBacked. (2026). heXem bio — Funding & Investors. Retrieved November 15, 2026, from https://www.vcbacked.co/company/hexem-bio
{{cite web |title=heXem bio — Funding & Investors |url=https://www.vcbacked.co/company/hexem-bio |website=VCBacked |access-date=November 15, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at heXem bio? Request a listing update